Skip to main content

Advertisement

SpringerLink
Log in

At what hip fracture risk is it cost-effective to treat?

International intervention thresholds for the treatment of osteoporosis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Introduction

Intervention thresholds (ITs), the 10-year hip fracture risk at which treatment can be considered to be cost-effective, have previously been estimated for Sweden and the UK.

Objective

The aim of this study was to provide a Markov cohort model platform for a multinational estimation of thresholds at which intervention becomes cost-effective and to investigate and determine the main factors behind differences in these thresholds between countries.

Results and discussion

Intervention thresholds were estimated for Australia, Germany, Japan, Sweden, Spain, the UK and USA using a societal perspective. The model was populated with as much relevant country-specific data as possible. Intervention was assumed to be given for 5 years and to decrease the risk of all osteoporotic fractures by 35%. The societal willingness to pay (WTP) for a quality-adjusted life-year (QALY) gained was set to the gross domestic product (GDP) per capita multiplied by two. In the base case analysis, the 10-year hip fracture probability at which intervention became cost-effective varied across ages and countries. For women starting therapy at an age of 70 years, the IT varied from a hip fracture probability of 5.6% in Japan to 14.7% in Spain. The main factors explaining differences in the IT between countries were the WTP for a QALY gained, fracture-related costs and intervention costs.

Conclusion

The ITs presented in this paper are appropriate for use in treatment guidelines that consider health economic aspects, and they can be used in combination with fracture risk prediction algorithms to improve the selection of patients who are suitable for osteoporotic intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Johannesson M (2001) At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 22:919–925

    Article  PubMed  CAS  Google Scholar 

  2. Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B (2002) Intervention thresholds for osteoporosis. Bone 31:26–31

    Article  PubMed  CAS  Google Scholar 

  3. Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14

    Article  PubMed  Google Scholar 

  4. Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B (2005) Intervention thresholds for osteoporosis in the UK. Bone 36:22–32

    Article  PubMed  Google Scholar 

  5. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427

    Article  PubMed  CAS  Google Scholar 

  6. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15–25

    Article  PubMed  CAS  Google Scholar 

  7. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862–871

    Article  PubMed  CAS  Google Scholar 

  8. Jonsson L, Borgstrom F, Zethraeus N (2003) Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial. Ugeskr Laeger 165:4112–4116

    PubMed  Google Scholar 

  9. Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100:36–40

    PubMed  Google Scholar 

  10. Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22:1153–1165

    Article  PubMed  Google Scholar 

  11. Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34:1064–1071

    Article  PubMed  Google Scholar 

  12. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314

    Article  PubMed  Google Scholar 

  13. Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383–388

    Article  PubMed  Google Scholar 

  14. Borgström F, Kanis JA, Johnell O, Jönsson B (2006) Are costs of fracture proportional to their morbidity?. Osteoporos Int ECCEO abstract 17[Suppl 2]:47

    Google Scholar 

  15. Borgström F, Kanis JA, Johnell O, Jönsson B (2006) Costing fractures for use in health economics modelling. Osteoporos Int ECCEO abstract 17[Suppl 2]: 97

    Google Scholar 

  16. ISPOR (2005) ISPOR pharmacoeconomic guidelines. http://www.ispor.org/PEguidelines/index.asp

  17. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146

    PubMed  CAS  Google Scholar 

  18. Jonsson B, Kanis J, Dawson A, Oden A, Johnell O (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193–199

    Article  PubMed  CAS  Google Scholar 

  19. Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142

    Article  PubMed  CAS  Google Scholar 

  20. Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9(22):1–160

    PubMed  CAS  Google Scholar 

  21. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26

    Article  PubMed  CAS  Google Scholar 

  22. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518–528

    Article  PubMed  Google Scholar 

  23. Commission on Macroeconomics and Health (2001) Report on macroeconomics and health: investing in health for economic development. WHO, Geneva

    Google Scholar 

  24. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB (2003) Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361:717–725

    Article  PubMed  Google Scholar 

  25. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349:1436–1442

    Article  PubMed  CAS  Google Scholar 

  26. Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38:583–637

    Article  PubMed  CAS  Google Scholar 

  27. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674

    Article  PubMed  CAS  Google Scholar 

  28. Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80:243–248

    Article  PubMed  CAS  Google Scholar 

  29. Elffors I, Allander E, Kanis JA, Gullberg B, Johnell O, Dequeker J, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis G et al. (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4:253–263

    Article  PubMed  CAS  Google Scholar 

  30. Euopean Commission – Employment and Social Affairs (1998) Report on Osteoporosis in the European Community - Action for Prevention. European Commission – Employment & Social Affairs, Brussels

    Google Scholar 

  31. Nagata-Kobayashi S, Shimbo T, Fukui T (2002) Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Metab 20:350–357

    Article  PubMed  Google Scholar 

  32. Melton LJ 3rd, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29–37

    Article  PubMed  Google Scholar 

  33. Sanders KM, Seeman E, Ugoni AM, Pasco JA, Martin TJ, Skoric B, Nicholson GC, Kotowicz MA (1999) Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int 10:240–247

    Article  PubMed  CAS  Google Scholar 

  34. Government Actuary´s Department. Interim Life Tables. http://www.gad.gov.uk/policy_and_stats/life_tables.htm. Access date: 2004-10-15

  35. Instituto Nacional del Estadistica (2002) Tablas de Mortalidad de la Población de España 1998–1999. Madrid

  36. Statistical Yearbook of Sweden (2004). Statistics Sweden, Stockholm

  37. Human Mortality Database. University of California, Berkeley (USA) and Max Planck Institute for Demographic Research (Germany)

  38. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473

    Article  PubMed  CAS  Google Scholar 

  39. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599–603

    Article  PubMed  CAS  Google Scholar 

  40. Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105:443–446

    Article  PubMed  CAS  Google Scholar 

  41. Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2005) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 1–14

  42. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38; discussion, pp 39–40

    Article  PubMed  CAS  Google Scholar 

  43. Brecht JG, Kruse HP, Felsenberg D, Mohrke W, Oestreich A, Huppertz E (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23:93–105

    PubMed  CAS  Google Scholar 

  44. Hart WM, Rubio-Terres C, Burrell A, Aristegui I, Escobar-Jimenez Y (2002) Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato. Rev Esp Enferm Metab Óseas 11:97–104

    Google Scholar 

  45. Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68:13–17

    Article  PubMed  CAS  Google Scholar 

  46. Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617

    Article  PubMed  CAS  Google Scholar 

  47. Kanis JA (2002) Epidemiology and costs of fractures in the UK: background document for male osteoporosis model. Personal communication

  48. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ 3rd (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323–330

    Article  PubMed  CAS  Google Scholar 

  49. OECD Health Data (2005)

  50. Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33–64

    Article  PubMed  CAS  Google Scholar 

  51. Ekman M, Zethraeus N, Jonsson B (2001) Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics 19:901–916

    Article  PubMed  CAS  Google Scholar 

  52. Meltzer D, Egleston B, Stoffel D, Dasbach E (2000) Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care 38:679–685

    Article  PubMed  CAS  Google Scholar 

  53. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237–1244

    Article  PubMed  Google Scholar 

  54. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589

    Article  PubMed  Google Scholar 

  55. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742

    Article  PubMed  Google Scholar 

  56. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194

    Article  PubMed  Google Scholar 

  57. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382

    Article  PubMed  CAS  Google Scholar 

  58. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ 3rd, Pols HA, Reeve J, Silman AJ, Tenenhouse A (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029–1037

    Article  PubMed  CAS  Google Scholar 

  59. De Laet C, Oden A, Johansson H, Johnell O, Jonsson B, Kanis JA (2005) The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 16:313–318

    Article  PubMed  Google Scholar 

  60. World Bank (2003) World development indicators. The World Bank, Washington, D.C.

    Google Scholar 

  61. Bacon WE, Maggi S, Looker A, Harris T, Nair CR, Giaconi J, Honkanen R, Ho SC, Peffers KA, Torring O, Gass R, Gonzalez N (1996) International comparison of hip fracture rates in 1988–89. Osteoporos Int 6:69–75

    Article  PubMed  CAS  Google Scholar 

  62. Johnell O, Gullberg B, Allander E, Kanis JA (1992) The apparent incidence of hip fracture in Europe: a study of national register sources. MEDOS Study Group. Osteoporos Int 2:298–302

    Article  PubMed  CAS  Google Scholar 

  63. Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women’s Health Initiative randomized controlled trial. Int J Technol Assess Health Care 21:433–441

    Article  PubMed  Google Scholar 

  64. Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365

    PubMed  CAS  Google Scholar 

  65. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197

    Article  PubMed  CAS  Google Scholar 

  66. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  67. Hillner BE, Hollenberg JP, Pauker SG (1986) Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med 80:1115–1127

    Article  PubMed  CAS  Google Scholar 

  68. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427

    Article  PubMed  CAS  Google Scholar 

  69. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728–735

    Article  PubMed  CAS  Google Scholar 

  70. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  PubMed  CAS  Google Scholar 

  71. Randell A, Sambrook PN, Nguyen TV, Lapsley H, Jones G, Kelly PJ, Eisman JA (1995) Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 5:427–432

    Article  PubMed  CAS  Google Scholar 

  72. Report on Government Services 2000 (2000) Canberra, Australia

  73. Stadsledningskontorets redovisningsstab. Stockholms stads budgetavräkning. http://www.stockholm.se Access date: 2004–08–22

  74. Netten A, Rees T, Harrison G; Unit Costs of health and Social Care (2002) Personal Social Services Research Unit, University of Kent

  75. MetLife Mature Market Institute (2003)

Download references

Acknowledgement

Financial support for this study was obtained from the International Osteoporosis Foundation.

Author information

Authors and Affiliations

  1. Medical Management Centre, Karolinska Institutet, Stockholm, Sweden

    F. Borgström & C. Rehnberg

  2. Stockholm Health Economics, Vasagatan 38 2tr, 111 20, Stockholm, Sweden

    F. Borgström

  3. Department of Orthopaedics, Malmö General Hospital, Malmö, Sweden

    O. Johnell

  4. Centre for Metabolic Bone Diseases (WHO Collaborating Centre), University of Sheffield Medical School, Sheffield, UK

    J. A. Kanis

  5. Stockholm School of Economics, Stockholm, Sweden

    B. Jönsson

Authors
  1. F. Borgström
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Johnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. A. Kanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Rehnberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Borgström.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borgström, F., Johnell, O., Kanis, J.A. et al. At what hip fracture risk is it cost-effective to treat?. Osteoporos Int 17, 1459–1471 (2006). https://doi.org/10.1007/s00198-006-0107-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-006-0107-0

Keywords

Search

Navigation